Relatlimab Plus Nivolumab Improves PFS in Patients With Previously Untreated Metastatic or Unresectable Melanoma

The ASCO Post Podcast

Konten disediakan oleh Harborside. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Harborside atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.

2+ y ago 11:46

MP3•Beranda episode

Seri yang sudah diarsipkan ("Feed tidak aktif" status)

When? This feed was archived on June 25, 2023 07:37 (10M ago). Last successful fetch was on May 05, 2023 17:56 (12M ago)

Why? Feed tidak aktif status. Server kami tidak mendapatkan feed podcast yang valid secara terus-menerus.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

On this episode, we’ll hear about a combination therapy that improved progression-free survival in previously untreated patients with melanoma. Then, we’ll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with immune checkpoint inhibitors.

Coverage of stories discussed this week on ascopost.com:

Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma

Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

To listen to more podcasts from ASCO, visit asco.org/podcasts.

185 episode

#Fitness #Harborside #Week In Review #Oncology #Science #Medicine